21 CFR 211.192
Table of Contents
Introduction
21 CFR 211.192, part of the U.S. Code of Federal Regulations, governs the pharmaceutical quality control system. This regulation ensures thorough investigation of any unexplained discrepancies or failures during drug production and quality testing, bolstering drug safety and efficacy.
Definitions and Concepts
21 CFR 211.192: Refers specifically to the mandate within Title 21, Part 211, Subpart J, which requires that all deviations or failures in batch production or quality control are fully investigated and documented.
Batch Record Review: A key component requiring the examination of manufacturing records to ensure compliance.
CAPA: Corrective and Preventive Actions aimed at addressing root causes of quality issues identified during investigations.
Importance
21 CFR 211.192 is vital for ensuring the integrity of the pharmaceutical manufacturing process. Adhering to this regulation:
- Enhances patient safety by minimizing the risk of defective or harmful drug products.
- Maintains compliance with FDA requirements, preventing financial and reputational penalties.
- Improves operational efficiency by addressing and preventing recurrent quality issues.
- Supports a culture of accountability within pharmaceutical and biotech organizations.
Principles or Methods
The implementation of 21 CFR 211.192 is guided by several quality principles, including:
- Root Cause Analysis: Dedication to finding and addressing the cause of deviations or failures.
- Thorough Documentation: All investigations must be comprehensively documented, detailing the issue, investigation process, findings, and corrective actions.
- Batch Integrity: Ensuring that no drug product or batch is distributed until all quality concerns are resolved.
- Preventive Systems: Using insights from investigations to establish safeguards against future occurrences.
- Audits and Inspections: Periodic review of compliance with regulatory requirements and quality systems.
Application
21 CFR 211.192 is applied extensively in pharmaceutical and biotech industries. Examples include:
- Batch Release Decision-making: Ensuring that all discrepancies are investigated and resolved before product release.
- Contamination Control: Quick response to unexpected contamination events by conducting investigations and implementing CAPA.
- Supplier Quality Oversight: Applying the regulation to ensure raw materials and component suppliers adhere to quality specifications.
- Adverse Event Reporting: Investigating adverse events linked to product quality and reporting findings to regulatory authorities.
- Regulatory Inspections: Serving as a focal point during FDA or international audits to demonstrate the effectiveness of quality systems.
References
For further reading and guidance on 21 CFR 211.192, refer to the following resources: